Holding: Amgen’s two patent applications — purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism — fail to satisfy the Patent Act’s enablement clause, see 35 U.S.C. § 112(a). Judgment: Affirmed, 9-0, in an opinion by Justice Gorsuch on May 18, 2023.  ABOUT
RESOURCES
JOB POSTINGS
PRIVACY POLICY
CONTACT US Sign up to receive a daily email
digest from follow.it by
entering your email.